| Market Cap | 179.57M | P/E | - | EPS this Y | 44.50% | Ern Qtrly Grth | - |
| Income | -107.87M | Forward P/E | -1.24 | EPS next Y | -11.60% | 50D Avg Chg | 8.00% |
| Sales | 29.38M | PEG | -0.19 | EPS past 5Y | - | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | 0.68 | EPS next 5Y | 22.30% | 52W High Chg | -72.00% |
| Recommedations | 2.10 | Quick Ratio | 4.89 | Shares Outstanding | 69.34M | 52W Low Chg | 41.00% |
| Insider Own | 11.65% | ROA | -19.25% | Shares Float | 46.09M | Beta | 3.06 |
| Inst Own | 88.47% | ROE | -44.87% | Shares Shorted/Prior | 11.92M/10.50M | Price | 3.66 |
| Gross Margin | -257.49% | Profit Margin | - | Avg. Volume | 1,284,451 | Target Price | 16.14 |
| Oper. Margin | -178.59% | Earnings Date | Oct 30 | Volume | 404,974 | Change | -1.35% |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| BMO Capital | Outperform | Aug 6, 24 |
| Wells Fargo | Equal-Weight | May 9, 24 |
| Stifel | Buy | May 9, 24 |
| Morgan Stanley | Equal-Weight | Feb 26, 24 |
| Stifel | Buy | Feb 23, 24 |
| JP Morgan | Neutral | Jan 29, 24 |
| Stifel | Buy | Dec 13, 23 |
| Morgan Stanley | Equal-Weight | Nov 6, 23 |
| BMO Capital | Outperform | Nov 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Anderson Kenneth Carl | Director Director | Jul 15 | Option | 3.55 | 1,424 | 5,055 | 90,986 | 07/18/22 |
| Fisher Stewart | Chief Scientific Off.. Chief Scientific Officer | Apr 12 | Option | 4.35 | 28,084 | 122,165 | 71,390 | 04/12/22 |
| Hirsch Andrew | President & CEO President & CEO | Apr 12 | Buy | 8.40 | 10,000 | 84,000 | 10,000 | 04/12/22 |
| Anderson Kenneth Carl | Director Director | Jan 26 | Option | 3.55 | 2,137 | 7,586 | 87,975 | 01/26/22 |